CARCINOMA, RENAL CELL
Clinical trials for CARCINOMA, RENAL CELL explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, RENAL CELL trials appear
Sign up with your email to follow new studies for CARCINOMA, RENAL CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kidney cancer: vorolanib tested as Second-Line therapy
Disease control Recruiting nowThis study tests the drug vorolanib in people with advanced kidney cancer that cannot be removed by surgery or has spread. It is for patients who need a second treatment after the first one stopped working. The goal is to see how long the drug controls the cancer and what side ef…
Matched conditions: CARCINOMA, RENAL CELL
Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated May 26, 2026 04:48 UTC
-
New hope for advanced cancers: experimental drug enters human trials
Disease control Recruiting nowThis study tests a new drug, BMS-986340, alone or with other cancer treatments (nivolumab or docetaxel) in people with advanced solid tumors that have worsened after standard therapy. The goal is to find safe doses and understand side effects. About 949 adults with various cancer…
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 26, 2026 04:32 UTC
-
Mushroom-Derived drug targets kidney cancer in dialysis patients
Disease control Recruiting nowThis early-stage trial tests a drug called orellanine in people with advanced kidney cancer who are also on dialysis due to end-stage kidney disease. The goal is to see if the drug is safe and can shrink tumors. Participants must have tried standard treatments without success.
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE1, PHASE2 • Sponsor: Oncorena AB • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug cocktail aims to extend lives in tough kidney cancer
Disease control Recruiting nowThis study tests whether adding a new targeted drug (zanzalintinib) to standard belzutifan therapy helps people with advanced kidney cancer live longer and keep their cancer from growing. About 758 adults whose cancer worsened after at least one prior treatment will receive eithe…
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for advanced kidney cancer: experimental drug enters human trials
Disease control Recruiting nowThis study tests a new medicine, PF-08634404, in adults with advanced kidney cancer that has spread. The goal is to see if it is safe and can shrink tumors when given alone or with other cancer drugs. About 224 participants will receive the drug through an IV. This is an early-ph…
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Hope for advanced cancers: Long-Term belzutifan trial opens
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of the drug belzutifan in people with advanced solid tumors or von Hippel-Lindau (VHL) disease. Participants must already be taking belzutifan in another study. The main goal is to see how long people live after starting …
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New combo aims to outsmart Drug-Resistant kidney cancer
Disease control Recruiting nowThis study tests whether adding bicalutamide to sunitinib can safely control advanced kidney cancer that has stopped responding to standard targeted therapy. About 28 adults will receive the combination to see if it shrinks tumors or slows disease progression. The goal is to find…
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE1, PHASE2 • Sponsor: State University of New York at Buffalo • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
AI reads CT scans to spot early vs. advanced kidney cancer
Diagnosis Recruiting nowThis study aims to train a computer model to automatically tell the difference between early (T1-T2) and more advanced (T3) kidney cancer on CT scans. Researchers will use scans from 1,000 patients to develop and test the AI tool. If successful, this could help doctors make more …
Matched conditions: CARCINOMA, RENAL CELL
Sponsor: Peking University First Hospital • Aim: Diagnosis
Last updated May 19, 2026 11:48 UTC